نتائج البحث

The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer*

• Authors : Tilki, Elif Kaya; Ozturk, Selin Engur

Subjects: Macrophage; polarisation; epigenetics

تفاصيل العنوان

Ixazomib, lenalidomide, and dexamethasone (IRD) treatment with cytogenetic risk-based maintenance in transplant-eligible myeloma: a phase 2 multicenter study by the Nordic myeloma study group /

• Authors : Partanen, Anu; Waage, Anders; Pečeliūnas, Valdas

Subjects: autologous stem cell transplantation; ixazomib; maintenance

• Source: Cancers., Basel : MDPI, 2024, vol. 16, iss. 5, art. no. 1024, p. [1-15]. ; eISSN 2072-6694

تفاصيل العنوان

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

• Authors : Anu Partanen; Anders Waage; Valdas Peceliunas

Subjects: multiple myeloma; ixazomib; autologous stem cell transplantation

• Source: Cancers, Vol 16, Iss 5, p 1024 (2024)

تفاصيل العنوان

Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis

• Authors : Frič Dominik; Štork Martin; Boichuk Ivanna

Subjects: daratumumab; ixazomib; relapsed/refractory multiple myeloma

• Source: European Journal of Haematology

تفاصيل العنوان

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.

• Authors : Groen, Kaz; Stege, Claudia A M; Nasserinejad, Kazem ...

Subjects: Daratumumab; Elderly; IMWG frailty index

• Source: EClinicalMedicine, Vol. 63, p. 102167 [1-12] (2023)

تفاصيل العنوان

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.

• Authors : Groen, Kaz; Stege, Claudia A M; Nasserinejad, Kazem ...

Subjects: Daratumumab; Elderly; IMWG frailty index

• Source: EClinicalMedicine, Vol. 63, p. 102167 [1-12] (2023)

تفاصيل العنوان

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma:an open-label phase 2 trial

• Authors : Groen, Kaz; Stege, Claudia A.M.; Nasserinejad, Kazem

Subjects: Daratumumab; Elderly; IMWG frailty index

• Source: Groen , K , Stege , C A M , Nasserinejad , K , de Heer , K , van Kampen , R J W , Leys , R B L , Thielen , N , Westerman , M , Wu , K L , Ludwig , I , Issa , D E , Velders , G A , Vekemans , M C ,

تفاصيل العنوان

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma

• Authors : Selina Bühler; Dilara Akhoundova; Barbara Jeker

Subjects: multiple myeloma; stem cell mobilization; autologous stem cell transplantation (ASCT)

• Source: Cancers; Volume 15; Issue 2; Pages: 430

تفاصيل العنوان

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context

• Authors : Kaz Groen; Claudia A.M. Stege; Kazem Nasserinejad

Subjects: Multiple myeloma; Elderly; Daratumumab

• Source: EClinicalMedicine, Vol 63, Iss , Pp 102167- (2023)

تفاصيل العنوان

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma

• Authors : Selina Bühler; Dilara Akhoundova; Barbara Jeker

Subjects: multiple myeloma; stem cell mobilization; autologous stem cell transplantation (ASCT)

• Source: Cancers, Vol 15, Iss 430, p 430 (2023)

تفاصيل العنوان